Market in sight for Pharmaxis
Wednesday, 20 August, 2008
Pharmaxis [ASX: PXS] has concluded a Phase 3 clinical trial of its Bronchitol treatment, confirming its safety in subjects with bronchiectasis.
None of the 99 subjects who concluded the trial experienced serious adverse effects attributable to the drug, even after a 12-month treatment schedule.
Some minor side effects were attributable to the medication, such as coughing and a sore throat, but these symptoms occurred in less than 10 per cent of the sample group.
Seven subjects did drop out of the trial after suffering adverse events – lung infections or chronic coughing – but it has not been demonstrated that Bronchitol was the cause of these effects.
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
